Sources checked October 18, 2026. FDA archive dates and the eCFR currency date are stated below. This is a research explainer, not a dosing guide or medical review.
What is KPV peptide?
K, P and V are the one-letter amino-acid codes in the name. FDA's May 12, 2026 evaluation distinguishes KPV free base from KPV acetate as separate bulk drug substances. A label saying only KPV leaves that distinction unstated.[1]
The research formulation also matters. A 2017 experiment enclosed KPV in hyaluronic-acid-functionalized nanoparticles and then a hydrogel. That preparation was not simply a capsule containing unmodified KPV.[5]
Is KPV FDA-approved or on the compounding list?
FDA's May 12, 2026 evaluation states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug. The document proposed not adding either to the 503A bulks list; it was a premeeting evaluation, not a final determination. We read the FDA original archived October 5, 2026.[1]
KPV is absent from the codified 503A inclusion list in 21 CFR 216.23(a), current through October 15, 2026 and checked October 18. It is also absent from that section's named noninclusion list. Those observations do not establish a final KPV-specific rejection.[2]
FDA's category page, archived October 11, 2026, places KPV among withdrawn nominations, described as previously in Category 2. Calling that entry a current Category 2 listing would misstate the table. Withdrawal is not a statement of drug approval.[3]
The exact July committee vote was not verified for this page. A meeting, nomination or advisory recommendation should not be presented as a final rule. The FDA briefing itself says a final determination follows advisory input and completed reviews.[1]
What have KPV studies measured?
These selected original reports illustrate different questions: cellular signaling, tissue measurements and delivery of a particular formulation. The study population and preparation are stated separately so an animal result is not mistaken for a patient response. This is a selected research summary, not a systematic review.
Dalmasso et al.: cells and mouse colitis models, 2008 issue
Dalmasso and colleagues studied intestinal and immune cell lines plus chemically induced colitis in mice. In the TNBS experiment, Figure 8 identifies ten mice per group and a 48-hour assessment. KPV was supplied in drinking water. The authors reported approximately 30 percent lower colonic myeloperoxidase activity relative to TNBS alone. That percentage describes an enzyme assay, not symptom relief in people.[4]
The separate DSS experiment's Figure 6 uses five mice per group. These denominators should not be pooled or applied to every result in the paper. Electronic publication was October 17, 2007; the journal issue is January 2008.[4]
Xiao et al.: oral nanoparticle delivery, 2017
Xiao and colleagues' original abstract describes KPV-loaded nanoparticles with an approximately 272.3 nm particle size. Oral delivery used a chitosan/alginate hydrogel in a mouse colitis model. The authors reported less mucosal damage and lower TNF-alpha measurements with the hyaluronic-acid-functionalized system than with the comparison nanoparticle/hydrogel system. The accessible abstract does not state the animal count or study duration; those details remain unknown here.[5]
Sung et al.: cultured skin cells, 2025
Sung and colleagues exposed human HaCaT keratinocytes to fine particulate matter and examined KPV in cell experiments and a three-dimensional skin model. Their original abstract reports changes in cell viability, reactive oxygen species and IL-1beta secretion. These were laboratory models, not enrolled patients. The abstract does not provide a complete experiment-by-experiment sample size or duration. Human-derived cells are not a human treatment trial.[6]
Cheng et al.: an engineered proKPV conjugate, 2026
Cheng and colleagues studied proKPV, a chemically engineered delivery conjugate, in mice. In the colonic-distribution experiment, the area under the fluorescence-time curve was 3.8 times that of the free labeled peptide. Figure 3 specifies three biological replicates; fluorescence was followed through 24 hours. This is a distribution measurement, not a 3.8-fold clinical benefit.[7]
A separate seven-day mouse-colitis experiment used six mice per group and measured body weight, disease-activity scores, colon length and tissue markers. Its results belong to proKPV under those experimental conditions, not every product labeled KPV. Two authors disclosed a pending patent related to the work.[7]
Has KPV been studied in people?
FDA's May 2026 evaluation reported finding no clinical-study data on KPV administered to humans. That is a dated finding from the agency's search, not a claim that every later or unpublished study has been ruled out.[1]
The 2025 skin-cell report does not fill that gap: its human-derived keratinocytes and three-dimensional model were laboratory systems. It cannot supply a patient response rate, a treatment duration for people or a recommended regimen.[6]
What should you ask about a KPV product or service?
Ask for the exact ingredient and chemical form, formulation, intended route, manufacturer or dispensing pharmacy, and the original source behind each claimed result. Keep the answers in writing. Ask whether the cited study tested that formulation or a different carrier, conjugate or blend.
Ask which current regulatory document the provider relies on, rather than accepting a reference to an advisory meeting as the answer. Request an itemized written quote if a service is offered. This page does not verify a seller, recommend purchasing KPV or supply an administration schedule.
Where can you browse related clinic listings?
Regenerated.com's September 2026 export contains 2,743 clinics listing Peptide Therapy within a sample of 9,042 US clinic records, across 49 states plus DC. Source: Regenerated.com clinic export, collected September 2026. This is historical directory category coverage, not a count of KPV prescribers, product availability or the US market.
Browse the Peptide Therapy clinic directory, or the Peptide Therapy clinics in Florida and Peptide Therapy clinics in Texas listings. Confirm the individual clinic's actual services separately. A listing is not an endorsement.
The broader Peptide Therapy guide provides category context. The directory count above does not establish that a listed clinic offers this particular substance.